Where do alternative vaccine administration routes fit in the clinical landscape?

Presented by

Prof. Marien de Jonge, Radboud University Medical Center, the Netherlands

Conference

ESCMID Vaccines 2025

The Intramuscular and subcutaneous routes are the traditional methods for vaccine delivery. Prof. Marien de Jonge (Radboud University Medical Center, the Netherlands) reviewed current data on vaccines administered via alternative routes.

The intradermal route is attractive due to the high density of antigen-presenting cells in the dermis, which may result in a potential dose-sparing effect. Currently, 3 vaccines have been licensed for intradermal administration: BCG, rabies, and some influenza vaccines. Intradermal administration requires specific skills. Microneedles and microneedle patches are alternative approaches to intradermal delivery, enabling slow antigen release and mimicking natural pathogen exposure [1]. This strategy has been tested in preclinical models with a slow-release, alum-containing HIV vaccine [2]. Moving closer to clinical practice, a microneedle patch vaccine for measles and rubella achieved nearly 100% seroconversion with only mild adverse events in a phase 1/2 study in children <18 months of age [3].

The mucosal route offers the advantage of stimulating large populations of resident memory T cells and tissue-resident B cells. However, only a single intranasal influenza vaccine is currently licensed [1]. One promising candidate, BPZE, is an intranasal live-attenuated pertussis vaccine evaluated in a phase 2b trial in healthy adults, where it induced nasal mucosal immunity and functional serum responses [4]. Intranasal COVID-19 vaccines are also in development; however, most remain in phase 1 [1,5].

“Intradermal and intranasal routes of administration offer significant potential and are gaining new relevance,” concluded Prof. de Jonge. “However, their adoption is limited by route-specific vaccine formulations and delivery mechanisms. This created the need to develop novel correlates of protection”, he added [1].

De Jonge M. New developments in vaccination administration routes (intradermal, inhalation, mucosal). 6th ESCMID Vaccines, 10–13 September 2025, Lisbon, Portugal.

Rodrigues KA, et al. Sci Transl Med. 2025;17(803):eadw7499.

Ikechukwu Adigweme, et al. Lancet. 2024;403(10439):1879-1892.

Keech C, et al. Lancet. 2023;401(10379):843-855.

Singh C, et al. NPJ Vaccines. 2023;8(1):125.

Medical Conferences

Where do alternative vaccine administration routes fit in the clinical landscape?

Table of Contents: ESCMID Vaccines 2025

Featured articles

Letter from the Editor

Real-world data confirm PCV20 effectiveness against pneumococcal disease in adults aged ≥65 years

ESCMID Vaccines 2025 Highlights Podcast

Pneumococcal Vaccination

A quarter of US children have incomplete pneumococcal vaccination by age 2

V116 shows promise for adults at risk of pneumococcal disease

Real-world data confirm PCV20 effectiveness against pneumococcal disease in adults aged ≥65 years

The V116 pneumococcal vaccine is a new option in children at risk for pneumococcal disease

Influenza and COVID-19 Vaccination

Omicron XBB.1.5 vaccination provides effective, but rapidly waning protection in immunocompromised individuals

Intranasal COVID-19 vaccine shows promising results in preclinical mouse models

Influenza vaccine in children shows moderate, broad protection during the 2024-2025 season

Lower age is linked to reduced uptake of influenza and COVID-19 vaccination

RSV vaccination and Immunisation

Combination respiratory vaccines show promise but face key challenges

Adjuvanted RSVPreF3 demonstrates high real-world effectiveness in the USA

RSV immunisation: Maternal versus direct infant immunisation

European pregnant women show openness to maternal RSV vaccination

Infants immunised with nirsevimab have a lower risk of respiratory-related recurrent hospitalisation

Adjuvanted RSVPreF3 can be co-administered with a COVID-19 mRNA vaccine in adults aged ≥50 years

Other Childhood and Routine Vaccinations

Pertussis vaccination: Could an intranasal vaccine help curb the rising cases of whooping cough?

Does the 2+1 vaccination schedule for Haemophilus influenzae type b increase case numbers?

Wastewater poliovirus detections in Europe may reflect seasonal infection patterns rather than consistent importation

Emerging and Future Vaccines

Where do we stand with vaccination for haemolytic streptococci?

The future looks promising for tuberculosis vaccination